Ken Moelis, Moelis & Company, discuss whether tax reform might help companies look for acquisition opportunities. » Read More
Buying Juno could help Celgene diversify its portfolio as its top-selling drug approaches patent expiration. » Read More
Uber and SoftBank completed their long-awaited investment agreement on Thursday. » Read More
Merck CEO Kenneth Frazier talks with CNBC's Meg Tirrell about his company's avoidance of tax inversion deals, as well as his views on the M&A environment and drug pricing.
"You walk in and are overwhelmed by the work that needs to be done and how bad it has gotten," said one potential buyer.
Discussing how moves like the Treasury's new tax inversion rules could affect mergers and acquisitions going forward with Martin Okner, SHM Corporate Navigators Managing Partner, and Nicholas Fortuna, Partner at Allyn & Fortuna
Discussing the Justice Department's suit to block the deal between Baker Hughes and Halliburton, with Brian Uhlmer, GMP Securities.
The Pfizer, Allergan merger effort has reignited a debate over corporate inversions, says Yevgeniy Feyman. But US jobs are not really at stake.
CNBC contributors Jared Bernstein and James Pethokoukis react to the regulatory change by the Treasury on taxes.
CNBC's David Faber provides perspective to the Pfizer and Allergan deal.
Allergan CEO Brent Saunders discusses going separate ways with Pfizer after new tax rules by the Treasury, and what investors can expect from Allergan's growth.
Allergan CEO Brent Saunders says his company was blindsided by the new tax rules by the Treasury.
Pfizer and Allergan called off their $160 billion merger after Treasury issued new rules aimed at blocking inversions. Allergan CEO Brent Saunders discusses the new tax rules, and what investors can expect from growth at Allergan going forward.
A failed $160 billion merger between Pfizer and Allergan left experts contemplating whether more deals could be hit by new tax rules.
The U.S. government hamstrings American businesses trying to compete overseas, says Grover Norquist, Americans for Tax Reform, sharing his thoughts on the problems with the U.S. tax aversion policy.
CNBC's Eamon Javers reports on the fallout from the Treasury Department's new action to prevent more corporations from fleeing the country to avoid paying their taxes.
It is now official, Pfizer and Allergan are calling off the deal to merge, reports "Squawk Box's" Andrew Ross Sorkin.
CNBC's Meg Tirrell's report on the possible end of a merger between Pfizer and Allergan as tax rules tighten.
The U.S. Justice Department will file a lawsuit as soon as this week to stop Halliburton Co from acquiring smaller rival Baker Hughes Inc.
Lothar Mentel, CIO of Tatton Investment Management, says the merger with Deutsche Boerse will streamline settlements and bring down costs.
Sachin Shah from Albert Fried and Company says it will be hard for Pfizer to come up with a back-up plan that will offer $2 billion of opportunities.
CEO Brent Saunders spoke after Pfizer and Allergan terminated their $160B merger because of surprise changes in U.S. tax regulations.
CNBC's Meg Tirrell and Ipsita Smolinski, Managing Director and Health Care Analyst at Capitol Street, discuss the implications for the Allergan/Pfizer deal and other multinational companies with the new tax inversion rules from the Treasury Department.
Get the best of CNBC in your inbox